Viruses,
Год журнала:
2023,
Номер
15(9), С. 1934 - 1934
Опубликована: Сен. 15, 2023
The
relationship
between
superinfection
by
multidrug-resistant
Gram-negative
bacteria
and
mortality
among
SARS-CoV-2
hospitalized
patients
is
still
unclear.
Carbapenem-resistant
Acinetobacter
baumannii
carbapenemase-producing
Enterobacterales
are
the
most
frequently
isolated
species
when
it
comes
to
hospital-acquired
superinfections
patients.Herein,
a
retrospective
study
was
carried
out
using
data
from
adult
for
COVID-19.
interaction
in-hospital
rectal
carriage
and/or
carbapenem-resistant
assessed.The
incidence
of
KPC-producing
Klebsiella
pneumoniae
30%.
Bloodstream
infection
pneumonia
due
occurred
in
20%
patients.
A
higher
Charlson
comorbidity
index
(OR
1.41,
95%
CI
1.24-1.59),
being
submitted
invasive
mechanical
ventilation/ECMO
≥
96
h
6.34,
3.18-12.62),
treated
with
systemic
corticosteroids
4.67,
2.43-9.05)
having
lymphopenia
at
time
admission
0.54,
0.40-0.72)
were
features
strongly
associated
mortality.Although
carriage,
bloodstream
infection/pneumonia
diagnosed
remarkable
percentage
COVID-19
patients,
their
impact
on
not
significant.
Further
studies
needed
assess
burden
antimicrobial
resistance
as
legacy
order
identify
future
prevention
opportunities.
Antimicrobial Agents and Chemotherapy,
Год журнала:
2022,
Номер
66(5)
Опубликована: Март 21, 2022
Cefiderocol
may
represent
a
therapeutic
option
for
carbapenem-resistant
Acinetobacter
baumannii
(CRAB)
infections,
but
clinical
data
are
limited.
This
is
an
observational
retrospective
study
conducted
in
the
University
Hospital
of
Pisa
including
consecutive
patients
with
CRAB
infections
(January
2020
to
August
2021).
Patients
were
divided
two
groups
according
antibiotic
treatment
received:
cefiderocol-
and
colistin-containing
regimens.
The
primary
outcome
was
30-day
mortality.
A
Cox
regression
analysis
performed
identify
factors
independently
associated
propensity
score
using
inverse
probability
weighting
(IPTW)
also
performed.
total
124
included:
47
(37.9%)
received
cefiderocol,
while
77
(62.1%)
Overall,
79
(63.7%)
had
bloodstream
infection
(BSI),
35
(28.5%)
ventilator-associated
pneumonia
(VAP)
10
(8.1%)
other
infections.
Thirty-day
mortality
higher
receiving
colistin-
compared
those
who
cefiderocol-containing
regimens
(55.8%
versus
34%,
Microorganisms,
Год журнала:
2022,
Номер
10(3), С. 495 - 495
Опубликована: Фев. 23, 2022
While
it
is
reported
that
COVID-19
patients
are
more
prone
to
secondary
bacterial
infections,
which
strongly
linked
the
severity
of
complications
disease,
coinfections
associated
with
not
widely
studied.
This
work
aimed
investigate
prevalence
and
antibiotic
resistance
profiles
among
hospitalised
patients.
Age,
gender,
weight,
identities,
sensitivity
were
collected
retrospectively
for
108
admitted
intensive
care
unit
(ICU)
non-ICU
ward
a
single
center
in
Saudi
Arabia.
ICU
(60%)
showed
significantly
higher
percentage
sputum
(74%)
blood
(38%)
samples,
compared
non-ICU.
Acinetobacter
baumannii
(56%)
Klebsiella
pneumoniae
most
prevalent
species
from
patients,
presenting
full
all
tested
antibiotics
except
colistin.
By
contrast,
samples
exhibited
infections
Escherichia
coli
(31%)
Pseudomonas
aeruginosa
(15%)
predominantly,
elevated
E.
piperacillin/tazobactam
trimethoprim/sulfamethoxazole.
alarming
correlation
between
multi-drug
resistant
coinfection
admission
requires
attention
precaution
prescribed
limit
spread
bacteria
improve
therapeutic
management.
Frontiers in Microbiology,
Год журнала:
2023,
Номер
14
Опубликована: Июнь 22, 2023
is
increasingly
associated
with
various
epidemics,
representing
a
serious
concern
due
to
the
broad
level
of
antimicrobial
resistance
and
clinical
manifestations.
During
last
decades,
International Journal of Antimicrobial Agents,
Год журнала:
2023,
Номер
62(1), С. 106825 - 106825
Опубликована: Апрель 22, 2023
Ventilator-associated
pneumonia
(VAP)
caused
by
carbapenem-resistant
Acinetobacter
baumannii
(CRAB)
in
patients
hospitalized
intensive
care
units
(ICUs)
is
an
important
and
challenging
complication,
including
with
coronavirus
disease
2019
(COVID-19).
Considering
the
poor
lung
penetration
of
most
antibiotics,
intravenous
colistin
due
to
pharmacokinetics/pharmacodynamics
at
infection
site,
choice
best
antibiotic
regimen
still
being
debated.
Viruses,
Год журнала:
2021,
Номер
13(11), С. 2110 - 2110
Опубликована: Окт. 20, 2021
Antimicrobial
resistance
is
an
urgent
threat
to
public
health
and
global
development;
in
this
scenario,
the
SARS-CoV2
pandemic
has
caused
a
major
disruption
of
healthcare
systems
practices.
A
narrative
review
was
conducted
on
articles
focusing
impact
COVID-19
multidrug-resistant
gram-negative,
gram-positive
bacteria,
fungi.
We
found
that,
worldwide,
multiple
studies
reported
unexpected
high
incidence
infections
due
methicillin-resistant
Journal of Infection and Public Health,
Год журнала:
2023,
Номер
16(3), С. 313 - 319
Опубликована: Янв. 11, 2023
Acinetobacter
baumannii
infection
is
a
serious
public
health
problem
because
it
highly
resistant
to
antimicrobial
therapy
and
causes
high
fatality
rate
in
critically
ill
patients.
The
aim
of
the
study
examine
demographics,
microbiological
findings,
clinical
presentation,
outcomes
multi-drug-resistant
respiratory
infections
adult
ICU
intubated
patients
during
COVID-19
pandemic.This
included
115
mechanically
ventilated
who
had
retrieved
from
samples
pandemic
Albaha,
Saudi
Arabia.
information
was
obtained
medical
laboratory
files.
Univariate
analysis
used
compare
gender,
infection,
outcomes.The
baumanni
among
6.2
%.
Almost
93
%
developed
ventilator-associated
pneumonia,
five
them
bacteremia.
isolates
significant
antibiotic
resistance
patterns,
which
3
were
pandrug-resistant
bacteria.
death
74
%,
with
major
risk
factors
including
sepsis,
septic
shock,
VAP,
liver
diseases,
use
inappropriate
that
lacked
both
colistin
tigecycline.
Patients
coinfection
worse
compared
non-COVID-19
patients.The
identification
MDR-AB
as
threat
highlights
importance
surveillance
studies
this
region.
Microorganisms,
Год журнала:
2023,
Номер
11(4), С. 984 - 984
Опубликована: Апрель 10, 2023
A
large
increase
in
multi-drug-resistant
Acinetobacter
baumannii,
especially
carbapenem-resistant
strains,
occurred
during
the
first
two
years
of
COVID-19
pandemic,
posing
important
challenges
its
treatment.
Cefiderocol
appeared
to
be
a
good
option
for
treatment
Carbapenem-resistant
baumannii
(CR-Ab),
but
date,
guidelines
and
evidence
available
are
conflicting.We
retrospectively
included
group
patients
with
CR-Ab
infections
(treated
colistin-
or
cefiderocol-based
regimens)
at
Padua
University
Hospital
(August
2020-July
2022)
assessed
predictors
30-day
mortality,
differences
microbiological
clinical
To
evaluate
difference
outcomes,
accounting
imbalance
antibiotic
allocation,
propensity
score
weighting
(PSW)
approach
was
adopted.We
111
patients,
68%
males,
median
age
69
(IQR:
59-78).
The
duration
13
days
(IQR:11-16).
In
total,
60
(54.1%)
51
(45.9%)
received
cefiderocol-
colistin-based
therapy,
respectively.
Notably,
53
(47.7%)
had
bloodstream
infections,
while
58
(52.3%)
pneumonia.
Colistin
combined
96.1%,
80.4%,
5.8%
cases
tigecycline,
meropenem,
fosfomycin,
13.3%,
30%,
18.3%
At
baseline,
groups
significantly
differed
(patients
treated
colistin
were
older),
prevalence
diabetes
obesity
(more
frequent
colistin),
length
stay
(longer
receiving
cefiderocol),
type
infection
(BSI
more
cefiderocol).
proportion
who
developed
acute
kidney
injury
higher
group.
By
using
PSW,
no
statistically
significant
emerged
mortality
cure
between
groups.
No
independent
detected
hospital
cure,
stay,
only
selected
predictor
age,
non-linear
effect
(p-value
0.025
non-linearity)
on
prolongation
0.25
(95%
CI
0.10-0.39)
increasing
ages
(calculated
over
IQR).Cefiderocol
did
not
differ
terms
main
outcomes
safety
profile
from
regimens.
More
prospective
studies
larger
number
required
confirm
our
results.
Viruses,
Год журнала:
2023,
Номер
15(9), С. 1843 - 1843
Опубликована: Авг. 30, 2023
Antibacterial
resistance
is
a
renewed
public
health
plague
in
modern
times,
and
the
COVID-19
pandemic
has
rekindled
this
problem.
Changes
antibiotic
prescribing
behavior,
misinformation,
financial
hardship,
environmental
impact,
governance
gaps
have
generally
enhanced
misuse
improper
access
to
antibiotics
during
pandemic.
These
determinants,
intersected
with
antibacterial
current
pandemic,
may
amplify
potential
for
future
The
occurrence
of
infections
multidrug-resistant
(MDR),
extensively
drug-resistant
(XDR),
difficult-to-treat
(DTR),
carbapenem-resistant
(CR),
pan-drug-resistant
(PDR)
bacteria
still
increasing.
aim
review
highlight
state
art
worldwide,
focusing
on
most
important
pathogens,
namely
Enterobacterales,
Acinetobacter
baumannii,
Klebsiella
pneumoniae,
their
common
antibiotics.
Microorganisms,
Год журнала:
2023,
Номер
11(5), С. 1299 - 1299
Опубликована: Май 16, 2023
Antibiotic
resistance
is
one
of
the
greatest
growing
public
health
threats
and
a
worldwide
priority.
According
to
WHO,
drug-resistant
diseases
may
cause
10
million
deaths
year
by
2050
have
substantial
impact
on
global
economy,
driving
up
24
people
into
poverty.
The
ongoing
COVID-19
pandemic
has
exposed
fallacies
vulnerability
healthcare
systems
worldwide,
displacing
resources
from
existing
programs
reducing
funding
for
antimicrobial
(AMR)
fighting
efforts.
Moreover,
as
already
seen
other
respiratory
viruses,
such
flu,
often
associated
with
superinfections,
prolonged
hospital
stays,
increased
ICU
admissions,
further
aggravating
disruption.
These
events
are
accompanied
widespread
antibiotic
use,
misuse,
inappropriate
compliance
standard
procedures
potential
long-term
AMR.
Still,
COVID-19-related
measures
increasing
personal
environmental
hygiene,
social
distancing,
decreasing
admissions
could
theoretically
help
AMR
cause.
However,
several
reports
shown
during
pandemic.
This
narrative
review
focuses
this
“twindemic”,
assessing
current
knowledge
in
era
focus
bloodstream
infections
provides
insights
lessons
learned
field
that
be
applied
stewardship
initiatives.
